8049 (8049) Fair Value & Analysis

Healthcare · Market cap HK$1.3B

8 8049 8049 · HK

PriceHK$2.30

Fair ValueHK$7.27

Upside+216.1%

Quality78/100

Watch 8049 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$5.51 – HK$9.02

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +5.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.38 – HK$2.60 · fair‑value band HK$5.51 – HK$9.02 · the HK$2.30 price screens below the HK$7.27 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8049 (8049) currently trades at HK$2.30, while our model-based Fair Value estimate is HK$7.27 — implying the stock looks roughly 216.1% undervalued today. We read business quality at 78/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 8049 generated revenue of HK$902M at a net margin of 22.1%. Revenue declined 5.1% year over year. It earns a return on equity of 12.0%. The balance sheet holds a net cash position of HK$143M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$902M

Revenue growth (YoY) -5.1%

Net margin 22.1%

Return on equity 12.0%

Free cash flow HK$301M FY2025

P/E ratio 5.6

More key figures

Operating margin 19.8%

EPS (TTM) HK$0.1800

EPS growth (YoY) +19.9%

Net cash HK$143M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8049 reported revenue of HK$902M in FY2025 versus HK$705M in FY2021, a compound +6.3%/yr. Reported net income was HK$199M in FY2025, compounding +8.5%/yr from FY2021.

Revenue +6.3%/yr

FY21 HK$705M

FY22 HK$842M

FY23 HK$842M

FY24 HK$881M

FY25 HK$902M

Net income +8.5%/yr

FY21 HK$143M

FY22 HK$194M

FY23 HK$148M

FY24 HK$184M

FY25 HK$199M

Is 8049 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8049 (8049) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$7.27 versus a price of HK$2.30 — about +216% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 8049?

Our model-based fair value for 8049 is HK$7.27 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.30.

What is the quality score of 8049?

8049 has a Quality Score of 78/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8049 (8049)?

8049 reported trailing-twelve-month revenue of about HK$902M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 8049?

The net profit margin of 8049 is about 22.1%, meaning it keeps roughly 22.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.